MetLife Investment Management’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $794K | Hold |
39,004
| – | – | ﹤0.01% | 1439 |
|
|
2025
Q1 | $708K | Sell |
39,004
-616
| -2% | -$11.2K | ﹤0.01% | 1532 |
|
|
2024
Q4 | $1M | Buy |
39,620
+2,288
| +6% | +$57.8K | 0.01% | 1413 |
|
|
2024
Q3 | $1.27M | Hold |
37,332
| – | – | 0.01% | 1257 |
|
|
2024
Q2 | $1.38M | Buy |
37,332
+5,568
| +18% | +$206K | 0.01% | 1169 |
|
|
2024
Q1 | $1.33M | Buy |
31,764
+7,691
| +32% | +$323K | 0.01% | 1142 |
|
|
2023
Q4 | $955K | Hold |
24,073
| – | – | 0.01% | 1319 |
|
|
2023
Q3 | $662K | Hold |
24,073
| – | – | 0.01% | 1463 |
|
|
2023
Q2 | $817K | Buy |
24,073
+349
| +1% | +$11.8K | 0.01% | 1382 |
|
|
2023
Q1 | $854K | Sell |
23,724
-901
| -4% | -$32.4K | 0.01% | 1310 |
|
|
2022
Q4 | $1.1M | Sell |
24,625
-583
| -2% | -$26K | 0.01% | 1178 |
|
|
2022
Q3 | $709K | Hold |
25,208
| – | – | 0.01% | 1388 |
|
|
2022
Q2 | $680K | Hold |
25,208
| – | – | 0.01% | 1449 |
|
|
2022
Q1 | $859K | Buy |
25,208
+9,152
| +57% | +$312K | 0.01% | 1430 |
|
|
2021
Q4 | $620K | Hold |
16,056
| – | – | 0.01% | 1394 |
|
|
2021
Q3 | $867K | Buy |
16,056
+1,549
| +11% | +$83.6K | 0.01% | 1194 |
|
|
2021
Q2 | $485K | Buy |
+14,507
| New | +$485K | ﹤0.01% | 1592 |
|
|
2018
Q2 | – | Sell |
-1,561
| Closed | -$55K | – | 2176 |
|
|
2018
Q1 | $55K | Sell |
1,561
-2,822
| -64% | -$99.4K | ﹤0.01% | 2169 |
|
|
2017
Q4 | $187K | Buy |
+4,383
| New | +$187K | ﹤0.01% | 1960 |
|